Healthcare Industry News: Bladder Cancer
News Release - December 14, 2009
BSD Medical Reports German Society of Radiation Oncology Press Release: Addition of Hyperthermia to Standard Therapy Is Effective for Treatment of Bladder CancerSALT LAKE CITY--(HSMN NewsFeed)--BSD Medical Corporation (NASDAQ: BSDM ) (www.bsdmedical.com) today announced that the German Society of Radiation Oncology (DEGRO) has issued a press release titled “Bladder Cancer – save the bladder with radiation and heat therapy.” The press release states that the addition of hyperthermia to standard radiation therapy (multimodal therapy) is effective for patients with aggressive Bladder Cancer who want to avoid removal of their bladder.
The primary objective for current Bladder Cancer treatments is to provide effective treatments that do not require removal of the bladder. The addition of hyperthermia to standard radiotherapy and chemotherapy (radiochemotherapy) improves these treatment results and increases the number of patients who can be effectively treated without removal of the bladder. Prof. Rita Engelhardt-Cabillic, the President of DEGRO, stated, "At the start of radiation therapy, they heat the bladder to 40 to 44 degrees Celsius using microwaves. The heat further increases the effect of the radiochemotherapy."
The press release was issued as a result of a published study that demonstrated an improvement in overall survival, tumor response rates and local tumor control from the addition of hyperthermia therapy delivered using the BSD-2000 Hyperthermia System to the standard treatment regimen. (M. Wittlinger, et al. “Quadrimodal treatment of high-risk T1 and T2 Bladder Cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.” Radiotherapy and Oncology, 93, 2009, 358.) The researchers stated that, in comparison to the results of a previous study they had conducted on trimodal treatment alone for Bladder Cancer patients, the addition of hyperthermia resulted in a higher overall survival rate (82% vs. 67% at five years) as well as local tumor control rate at three years (81% vs. 63%).
The German Society of Radiation Oncology (DEGRO – Deutsche Gesellschaft für Radio-Onkologie) is the largest radiation oncology organization in Germany and has more than 2,500 members. The world’s longest running scientific journal in radiation oncology, “Strahlentherapie und Onkologie,” is the official publication of DEGRO.
About BSD Medical Corporation
BSD Medical’s product line includes systems that have been strategically designed to offer a range of thermal treatment. The BSD-2000 is restricted to investigational use in the US. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.